Issue

Vol. 34 No. 10 (2022): Vol 34 Issue 10, 2022

Copyright (c) 2022 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Ultra Trace Level Detection and Quantification of Identified Genotoxic Impurity Ethyl (1R,5R,6R)-7-(tert-butyl)-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate in Oseltamivir Phosphate Drug Substance by Liquid Chromatography-Mass Spectrosco

https://doi.org/10.14233/ajchem.2022.23910
Ravi Kumar Puppala
Department of Chemistry, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu-515002, India
Nelaturi Subbaiah
Department of Chemistry, Jawaharlal Nehru Technological University Anantapur, Ananthapuramu-515002, India
K. Sesha Maheswaramma
Department of Chemistry, Jawaharlal Nehru Technological University College of Engineering, Pulivendula, Kadapa-560390, India

Corresponding Author(s) : Ravi Kumar Puppala

ravikpuppala@gmail.com

Asian Journal of Chemistry, Vol. 34 No. 10 (2022): Vol 34 Issue 10, 2022

Abstract

A new rapid run time LC-MS method was developed and validated for detection (0.03 ppm) and quantification (0.1 ppm) in ultra-trace level of genotoxic impurity (GTI) ethyl-(1R,5R,6R)-7-(tert-butyl)-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate in oseltamivir phosphate active pharmaceutical ingredient (API). The method is price effective, time redeemable and capable to confirm the parent and daughter ion masses through mass spectrometry and tandem mass spectrometry for further fragmentation. An isocratic program and YMC Pack Pro C4 reverse phase column (150 mm × 4.6 mm × 3.0 μm) was used to achieve separation between oseltamivir phosphate and ethyl-(1R,5R,6R)-7-(tert-butyl)-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate impurity. Mobile phase-A used was 0.01 M ammonium acetate in water and mobile phase-B used was acetonitrile in the ration of 40:60 v/v. Diluent was used methanol. The chromatographic conditions were used, injection volume: 20 μL, flow rate: 1.0 mL/min, oven temperature: 50 ºC, auto sampler: 5 °C and run time 8.0 min. The detection and quantification levels found at 0.03 and 0.1 ppm, respectively. Ethyl (1R,5R,6R)-7-(tert-butyl)-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate impurity is linear from 0.1 to 15 ppm levels with regression coefficient 0.9994. The recoveries were found in the range of 93.8% to 105.0%.

Keywords

Oseltamivir phosphate Multiple reaction monitoring LC-MS/MS Genotoxic impurity
Kumar Puppala, R., Subbaiah, N., & Sesha Maheswaramma, K. (2022). Ultra Trace Level Detection and Quantification of Identified Genotoxic Impurity Ethyl (1R,5R,6R)-7-(tert-butyl)-5-(pentan-3-yloxy)-7-azabicyclo[4.1.0]hept-3-ene-3-carboxylate in Oseltamivir Phosphate Drug Substance by Liquid Chromatography-Mass Spectrosco. Asian Journal of Chemistry, 34(10), 2583–2586. https://doi.org/10.14233/ajchem.2022.23910
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. T. Jefferson, M. Jones, P. Doshi, E.A. Spencer, I. Onakpoya and C.J. Heneghan, Br. Med. J., 348, g2545 (2014); https://doi.org/10.1136/bmj.g2545
  2. L. Müller, R.J. Mauthe, C.M. Riley, M.M. Andino, D.D. Antonis, C. Beels, J. DeGeorge, A.G.M. De Knaep, D. Ellison, J.A. Fagerland, R. Frank, B. Fritschel, S. Galloway, E. Harpur, C.D.N. Humfrey, A.S. Jacks, N. Jagota, J. Mackinnon, G. Mohan, D.K. Ness, M.R. O’Donovan, M.D. Smith, G. Vudathala and L. Yotti, Regul. Toxicol. Pharmacol., 44, 198 (2006); https://doi.org/10.1016/j.yrtph.2005.12.001
  3. D. Jacobson-Kram and T. McGovern, Adv. Drug Deliv. Rev., 59, 38 (2007); https://doi.org/10.1016/j.addr.2006.10.007
  4. European Medical Agency Guidence: Guidelines on the Limits of Genotoxic Impurities, MEA/CHMP/QWP/251344/2006 and EMA/CHMP/SWP/431994/2007 Rev.3, 23 September (2010).
  5. Guidelines for Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk, M7 ICH (2014).
  6. A.B. Patel, A.H. Asnani, A.J. Vyas, N.K. Patel, A.I. Patel and A.N. Lumbhani, Asian J. Pharm. Res., 11, 187 (2021); https://doi.org/10.52711/2231-5691.2021.00034
  7. A. Amberg, L. Beilke, J. Bercu, D. Bower, A. Brigo, K.P. Cross, L. Custer, K. Dobo, E. Dowdy, K.A. Ford, S. Glowienke, J. Van Gompel, J. Harvey, C. Hasselgren, M. Honma, R. Jolly, R. Kemper, M. Kenyon, N. Kruhlak, P. Leavitt, S. Miller, W. Muster, J. Nicolette, A. Plaper, M. Powley, D.P. Quigley, M.V. Reddy, H.-P. Spirkl, L. Stavitskaya, A. Teasdale, S. Weiner, D.S. Welch, A. White, J. Wichard and G.J. Myatt, Regul. Toxicol. Pharmacol., 77, 13 (2016); https://doi.org/10.1016/j.yrtph.2016.02.004
  8. Y.K. Sharma, D.D. Agarwal, S. Bhure, S.S. Rathore, C. Rawat and R. Mukharjee, E-J. Chem., 9, 113 (2012); https://doi.org/10.1155/2012/327351
  9. M. Shibasaki and M. Kanai, Eur. J. Chem., 2008, 1839 (2008); https://doi.org/10.1002/ejoc.200800033
  10. G.C. Reddy, P. Shyamala, R.M. Krishna, K.M.V. Narayanarao and D.B. Rapeti, Asian J. Pharm. Clin. Res., 14, 161 (2021); https://doi.org/10.22159/ajpcr.2021.v14i4.40595
  11. Z. Aydogmus, S. Çaglar and S. Toker, Anal. Lett., 43, 2200 (2010); https://doi.org/10.1080/00032711003698721
  12. Z. Ji, W. Song, X. Yan and C. Ai, J. Pharm. Sci. Technol. Manag., 3, 1 (2019); https://doi.org/10.11648/j.pst.20190301.11
  13. P. Raghuram, I.V. Soma Raju, R. Reddy and J. Sriramulu, Anal. Chem. An Indian J., 7, 617 (2008).
  14. B. Narasimhan, K. Abida and K. Srinivas, Chem. Pharm. Bull., 56, 413 (2008); https://doi.org/10.1248/cpb.56.413
  15. A. Ameti, J. Slavkovska, K. Starkoska and Z. Arsova-Sarafinovska, Maced. J. Chem. Chem. Eng., 31, 205 (2012); https://doi.org/10.20450/mjcce.2012.10
  16. K. Bhattacharya and J. Mathew, Future J. Pharm. Sci., 7, 95 (2021); https://doi.org/10.1186/s43094-021-00248-w
  17. C.R. Gudibanda, S. Pulipaka, M.K. Rallabhandi, M.V.N.R. Kapavarapu and M.D.B. Mannem, Future J. Pharm. Sci., 8, 15 (2022); https://doi.org/10.1186/s43094-022-00401-z
  18. P. Viswanath, D.V.R. Reddy and N. Chamarthi, Orient. J. Chem., 37, 1192 (2021); https://doi.org/10.13005/ojc/370525
  19. S. Reddy, N. Nayak, I. Ahmed, L. Thomas, A. Mukhopadhyay and S. Thangam, Asian J. Pharm. Anal., 6, 91 (2016); https://doi.org/10.5958/2231-5675.2016.00014.4
  20. A. Gupta, S. Guttikar, P.S. Shrivastav and M. Sanyal, J. Pharm. Anal., 3, 149 (2013); https://doi.org/10.1016/j.jpha.2012.11.004
  21. O. Kiguchi, T. Ishii, T. Watanabe, R. Konno, A. Matsubuchi and T. Kobayashi, Int. J. Environ. Anal. Chem., 100, 346 (2020); https://doi.org/10.1080/03067319.2019.1637425
  22. M.D. Green, H. Nettey and R.A. Wirtz, Emerg. Infect. Dis., 14, 552 (2008); https://doi.org/10.3201/eid1404.061199
  23. H. Chabai, R. Ouarezki, S. Guermouche and M.H. Guermouche, J. Liq. Chromatogr. Relat. Technol., 34, 1913 (2011); https://doi.org/10.1080/10826076.2011.582212
  24. H.B. Ila and A. Ilhan, Cytotechnology, 64, 443 (2012); https://doi.org/10.1007/s10616-011-9422-1
  25. D.S. Sisodiya, A. Soni, R. Patel, U.S.R. Majji and P. Khirwadkar, Res. J. Pharm. Technol., 5, 635 (2012).
  26. G. Szekely, M.C.A. de Sousa, M. Gil, F.C. Ferreira and W. Heggie, Chem. Rev., 115, 8182 (2015); https://doi.org/10.1021/cr300095f
  27. ICH Validation of Analytical Procedures: Text and Methodology Q2 (R1), International Conference on Harmonization (2005).
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 3 Download : 1